Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

Key Figures

SEM deal price: $16.50 per share DAWN deal price: $21.50 per share VRE deal price: $19.00 per share +2 more

5 metrics

SEM deal price $16.50 per share Cash sale of Select Medical Holdings (SEM) to executive-led consortium

DAWN deal price $21.50 per share Cash sale of Day One Biopharmaceuticals (DAWN) to Servier

VRE deal price $19.00 per share Cash sale of Veris Residential (VRE) to investor consortium

Contact phone (212) 763-0060 Law firm shareholder contact number

Office floor 85th Floor Halper Sadeh LLC office location at One World Trade Center

Market Reality Check

Price: $21.40 Vol: Volume 3,294,802 is at 0....

low vol

$21.40 Last Close

Volume Volume 3,294,802 is at 0.39x the 20-day average of 8,542,432, suggesting limited reaction. low

Technical Shares at $21.40 are above the 200-day MA of $9.31 and near the 52-week high of $21.46.

Peers on Argus

DAWN is roughly flat (0.14%) while key biotech peers like AVBP, TNGX and PRAX sh...

DAWN is roughly flat (0.14%) while key biotech peers like AVBP, TNGX and PRAX show declines between about -0.36% and -3.59%, indicating stock-specific factors tied to the Servier deal rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Legal investigation	Neutral	+0.1%	Law firm reviews fairness of DAWN’s agreed sale terms for shareholders.
Mar 09	Legal investigation	Neutral	+0.6%	Another law firm inquiry into whether DAWN shareholders receive fair value.
Mar 06	Acquisition announced	Positive	+65.9%	Servier agrees to acquire DAWN for $21.50 per share, ~$2.5B equity value.
Feb 24	Earnings report	Positive	-9.1%	Strong OJEMDA revenue growth and reaffirmed 2026 guidance accompany wider net loss.
Feb 10	Earnings date set	Neutral	-2.6%	Company schedules Q4 and full-year 2025 results and investor call.

Pattern Detected

Acquisition-related headlines have coincided with a large positive move, while strong earnings previously saw a negative reaction, indicating mixed alignment between fundamentals and price.

Recent Company History

Over recent months, DAWN’s trajectory has been defined by its acquisition by Servier at $21.50 per share and prior strong OJEMDA growth. The March 6 acquisition announcement triggered a sharp positive move, while February 24 earnings with significant revenue growth saw a negative reaction. Subsequent law-firm fairness investigations on March 9 and March 12 coincided with only minor price changes, suggesting these legal solicitations have not materially altered trading around the agreed deal terms.

Market Pulse Summary

This announcement highlights another law-firm review of whether DAWN’s agreed sale at $21.50 per sha...

Analysis

This announcement highlights another law-firm review of whether DAWN’s agreed sale at $21.50 per share offers fair value to shareholders. Prior similar notices earlier in March saw only modest price moves compared with the sharp reaction to the original Servier acquisition news. Investors following this situation may focus on tender offer progress, regulatory filings, and any revised terms, while considering that past earnings strength did not always translate into supportive short-term price action.

Key Terms

federal securities laws, fiduciary duties, contingent fee

3 terms

federal securities laws regulatory

"investigating the following companies for potential violations of the federal securities laws"

Federal securities laws are the set of national rules that require companies and market participants to provide accurate information, prohibit deceptive practices, and ensure fair trading of stocks and bonds. Think of them as the rules of the road for financial markets: they help investors make informed choices by mandating disclosures and punishing fraud, which reduces risk and builds trust in the safety and reliability of investments.

fiduciary duties regulatory

"and/or breaches of fiduciary duties to shareholders relating to"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

contingent fee financial

"on a contingent fee basis, whereby you would not be responsible"

A contingent fee is a payment arrangement where a party — often a lawyer, adviser or broker — gets paid only if a specified result is achieved, such as winning a case, completing a deal or recovering funds. For investors, contingent fees matter because they shift risk from the client to the service provider, can influence the timing and size of payments, and create incentives that may affect negotiation, litigation or deal strategies, similar to hiring a contractor who gets paid only when a job is finished successfully.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 27, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Select Medical Holdings Corporation (NYSE: SEM)'s sale to a consortium led by Select Medical executives and directors for $16.50 in cash per share. If you are a Select Medical shareholder, click here to learn more about your rights and options.

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)'s sale to Servier for $21.50 per share in cash. If you are a Day One shareholder, click here to learn more about your rights and options.

Veris Residential, Inc. (NYSE: VRE)'s sale to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners for $19.00 per share. If you are a Veris shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-sem-dawn-vre-obtaining-fair-deals-for-their-shareholders-302727048.html

SOURCE Halper Sadeh LLP